The TDG Board of Directors is comprised of distinguished UCLA faculty and executives from a range of industries, including biopharmaceuticals, engineering, finance, private equity, and venture capital. Board members provide guidance in making strategic investment decisions, oversight and direction to TDG's activities.
Board of Directors
William Mitchell, Chairman
William E. (Bill) Mitchell is the founding partner of Sequel Venture Partners, LLC, formed in January 2010 to invest in managed IT services companies utilizing venture capital, private equity and other investment vehicles. Prior to this, Mr. Mitchell was chairman of the board and chief executive officer of Arrow Electronics, Inc., a $20 billion Fortune 150 company providing advanced supply chain solutions to the technology industry. He joined Arrow in February 2003 as president and chief executive officer. He was named chairman of the board in May 2006. Mr. Mitchell retired as chairman of the board and chief executive officer on January 1, 2010.
Mr. Mitchell began his career in 1973 at Raychem Corporation, where he spent 20 years in various roles of increasing responsibility in finance, manufacturing operations, international operations, and worldwide sales and marketing. In 1993, he was named president and chief executive officer of Nashua Corporation, a manufacturer of specialty products and services for print application needs. In 1995, he became chairman, president and chief executive officer of Sequel, Inc., then a privately held computer services and maintenance company. Prior to joining Arrow, Mr. Mitchell sold Sequel, Inc. to Solectron Corporation, and then led the successful formation of Solectron Global Services, a $1.2 billion technology services company, now part of Flextronics International.
Currently, Mr. Mitchell serves on the Boards of Directors of Rogers Corporation where he serves as lead independent director; Humana Incorporated, where he serves on the Audit and Nominating/Governance Committees; and Spansion Incorporated, where he serves as chair of the Nominating/Governance Committee as well as the Compensation Committee. He served on the Board of Directors of National Semiconductor prior to its sale to Texas Instruments, as well as the Brown-Forman Corporation, where he was chair of the Audit Committee. He is chair-elect of the UCLA Foundation and serves on the Board of the UCLA Foundation, the UCLA Investment Company, and the Board of Trustees at the Menlo School in Atherton, California, where he serves on the Executive Committee.
Tom Unterman, Chairman Emeritus
Tom is the founding partner of Rustic Canyon Partners, one of the largest venture capital firms in Los Angeles. Through Rustic Canyon, he has raised venture funds in excess of $800 million. Among his notable investments are Netscape, LoopNet, Glass Lewis, and Fulcrum Bioenergy. Prior to forming Rustic Canyon Partners, Mr. Unterman had a long career as a corporate executive. From 1992 to 1999, he held several executive positions at Times Mirror Company, including Executive Vice President and Chief Financial Officer. At Times Mirror, he led the acquisition and divestiture activity and oversaw the investment program. Prior to joining Times Mirror, Tom was one of California’s leading corporate attorneys, practicing first with Orrick, Herrington from 1969 to 1986 and then with Morrison & Foerster from 1986 to 1992.
Tom also serves as the Chairman of the Board of MediaSpan Group, Inc., and a Director of Agribuys, Bassoe Offshore, FoodLink Online, LLC, The Deal, LLC, SLS Breeze Holdings, Inc., Practice Technologies, and RiverOne, Inc. He has been a Director of Fulcrum BioEnergy, Inc. since August 2007, Element K Corporation since February 2000 and WorldRes.com, Inc. since March 1999. He serves as a Director of Néo-Soft NSI SA, Transonic Combustion, Inc., ODS-Petrodata, Inc.(alternate name IHS-Petrodata, Inc.), Good Technology, Inc., Intrepid Learning Solutions, Inc., Navigating Cancer, Inc., RealPractice, Inc. and iCopyright, Inc. He serves as a Member of the Advisory Board at US Renewables Group, LLC. He has been a Member of Advisory Board at BlackLine Systems, Inc. since March 10, 2011.
Tom serves actively on the boards of the California Community Foundation, CalArts, Heal the Bay, and MOCA.
Norman served as acting chancellor of UCLA in 2006-2007. He retired from the Law School faculty in 2007 with the titles of Acting Chancellor Emeritus and Distinguished Professor of Law Emeritus, but he has been recalled and continues to teach and write in the areas of anti-terrorism law, federal criminal law and evidence.
Abrams joined the UCLA Law School faculty and has been a member of the UCLA family since 1959. From 1991 to 2001 he served as UCLA's vice chancellor of academic personnel, overseeing faculty appointments and promotions on the campus. He served as interim dean of the law school from 2003 to 2004, and earlier had served as associate dean, from 1989 to 1991. In May, 2012, Abrams received the award of highest distinction conferred by the UCLA Emeriti Association, which is their Lifetime Distinguished Service Award.
The fifth edition of Abrams' groundbreaking casebook on federal criminal law, Federal Criminal Law and Its Enforcement (with Beale and Klein), was published in 2010. Another of his books, Anti-Terrorism and Criminal Enforcement, (4th edition, 2012), is the first casebook to deal comprehensively with the rapidly evolving field of anti-terrorism law and the criminal enforcement process. He is also a co-author of Evidence - Cases and Materials (with Judge Jack B. Weinstein, et al.). Over his long career, he has written on many subjects, including prosecutorial discretion, federal jurisdiction, conspiracy law, evidentiary privileges and, more recently, anti-terrorism.
Before joining UCLA, Abrams served as an associate in law at Columbia University Law School and as a research associate and director of Harvard-Brandeis Cooperative Research for Israel's Legal Development at the Harvard Law School. He has also been a consultant to various state and federal commissions and professional committees, and, while on leave from UCLA, in 1966-67, he was appointed a special assistant to the Attorney General of the United States, serving in the Criminal Division of the U.S. Department of Justice. He has taught as a visiting professor at Stanford University Law School, UC Berkeley Law School, the Hebrew University Faculty of Law, Bar-Ilan School of Law, University of Southern California Law School and Loyola University (Los Angeles) School of Law.
Dr. Fabrizio Bonanni retired in 2013 from his position as executive vice president at Amgen, the world’s largest independent biotechnology company. In his 14 years with Amgen, he served as senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and finally EVP Operations, overseeing the company's global production and supply chain activities as well as Quality, Process Development, Drug Delivery Devices, Engineering, and Environment, Health and Safety.
While at Amgen, Bonanni served as a Trustee of the California Science Center, of the Los Angeles Museum of Contemporary Art, of the Science Technology and Research Trust of Puerto Rico, and as a member of the Board of the California Healthcare Institute. He also served on the Executive Committee of the Board of BIO, the Biotechnology Industry Association and co-chaired its Intellectual Property Committee.
Previously, he was corporate vice president, Regulatory and Clinical Affairs and corporate vice president, Quality System for Baxter International Inc., a company he joined in 1974, in Italy. At Baxter, Bonanni spent half of his career in international operations, including more than eight years at the company's European headquarters in Brussels, Belgium.
Bonanni earned his doctorate in chemistry, summa cum laude, mention of honor, from the University of Florence and did postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management, and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration.
Currently, Dr. Bonanni is a member of the board of directors and chair of the Internal Audit Committee of the Stevanato Group, an Italian company developing and manufacturing high quality primary containers, equipment, and devices for the bio-pharma industry. He also serves on the Advisory Board of InCube Labs, a San Jose, California, based company dedicated to the discovery and development of innovative medical technologies.
Michael J. Cleare
From 2000-2007, Mike was the Executive Director of Science and Technology Ventures at Columbia University in New York. This position included responsibility for all technology transfer activities at Columbia and involved licensing, spin off/start up companies, industrial research funding and domestic and international partnerships relating to IP. In August 2007, Mike joined the University of Pennsylvania as Associate Vice Provost for Research, responsible for all technology transfer, IP management and industrial liaison activities.
Before joining Columbia University, Mike Cleare worked for 30 years at Johnson Matthey, a UK-based multinational world leader in advanced materials technology. His experiences range from the Senior R&D Executive through Business Development to a range of senior business management positions, and included service on the main Board of the Company for four years. While in R&D, Mike was involved in the discovery and development of a major new class of anti-cancer drugs; he is credited as one of the inventors of the platinum-based drug carboplatin. He served as President of several of the company's major divisions, including Pharmaceutical Materials, Chemicals and Metals, Catalytic Systems and Electronic Materials. He has managed complex global business, negotiated and closed multi-million dollar licensing and technology transfer deals, and entered into multiple research funding agreements with major universities. For nine years, Mike was a member of the board of directors of the Canadian biotechnology company, AnorMed, which he helped to spin off from Johnson Matthey in 1996. He has published more than 40 articles and papers and holds 10 patents.
Dr. Cleare serves as a member of the Board of Directors, Arizona Technology Enterprises (AzTE), the exclusive intellectual property management and technology transfer organization for Arizona State University.
Michael Dal Bello
Michael is an Investment Partner at Pritzker Private Capital leading the firm’s Healthcare sector investing. Prior to joining Pritzker Private Capital, Michael was a Managing Director at Blackstone Capital Partners, with an aggregate $63 billion of assets under management in private equity. During his tenure at Blackstone, Michael helped lead sourcing efforts in healthcare and insurance, investing more than $7 billion of equity capital in 13 transactions. Michael also served on ten corporate boards, working with management teams to drive value through operational improvements, acquisitions and divestitures. Before joining Blackstone, Michael was an Associate at Hellman & Friedman where he was involved with the analysis and execution of private equity investments in the media and professional services sectors. Prior to that, Michael worked as a consultant at Bain & Company and also was a Research Associate at the China Center for Economic Research in Beijing, PR China as a Luce Scholar.
Michael earned an MBA from Harvard Business School, an MA from Oxford University and undergraduate degrees from the Wharton School and the College of Arts and Sciences at the University of Pennsylvania. He is a member of the Council on Foreign Relations.
Judith C. Gasson, a professor of biological chemistry and medicine, became director of UCLA’s Jonsson Comprehensive Cancer Center in 1995. A molecular biologist, Gasson is responsible for one of only 39 institutions nationwide designated as comprehensive cancer centers by the National Cancer Institute. In addition to her administrative duties, Gasson also is a gifted scientist. She was instrumental in purifying for the first time a hormone-like substance that increases the speed of bone marrow cell reproduction. That substance, called GM-CSF, is used to help prevent infections in cancer patients, and to allow patients to tolerate more chemotherapy and radiation than had previously been possible. In 2005, Gasson was named a co-director of the UCLA Institute of Stem Cell Biology and Medicine and she recently testified before a key Senate subcommittee on the promise of stem cell research in cancer. Gasson also serves as a board member for the American Association for Cancer Research. She earned a bachelor’s degree in microbiology from Colorado State University and a doctorate in physiology at the University of Colorado. Gasson did post doctoral work at the Salk Institute in La Jolla. In 1983, she left the Salk Institute to join UCLA's Jonsson Cancer Center, which comprises more than 240 researchers and clinicians engaged in research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating the results into leading-edge clinical studies. In July 2005, the Jonsson Cancer Center was named the best cancer center in the western United States by U.S. News & World Report, a ranking it has held for six consecutive years.
David has spent the past 25 years working to assist clients’ life science innovation strategies. This work has included a range of portfolio, drug development, investment, transactional and partnering strategies. While the therapeutic span of David’s work has crossed a broad swath of medicine, particular areas of focus have included: oncology, immunology, infectious disease as well as rare and orphan segments.
Prior to joining ClearView, David spent the majority of his career as a Managing Director of The Frankel Group in NYC and Israel ultimately serving as Managing Director and lead of Huron’s Life Science Strategy team. Most recently, David served as Global Head-Portfolio Management, Business Development & Licensing, at Novartis Oncology. In addition to client work, David has spent time teaching life sciences to business students and business to medical students and has published across drug pricing and reimbursement as well as innovation ecosystem economics.
David holds a A.B., with honors, in East Asian History from the University of Chicago and an MBA from the University of Texas at Austin.
Carl E. Gulbrandsen
Carl E. Gulbrandsen is the Emeritus Managing Director of Wisconsin Alumni Research Foundation (WARF). WARF is the patent management organization for the University of Wisconsin Madison. He has a Ph.D. in physiology and a J.D. degree, both from UW –Madison. Gulbrandsen was with WARF from October, 1997 until July,2016. Prior to becoming its Managing Director in 2000, Gulbrandsen was WARF’s Director of Patents & Licensing. Prior to his employment at WARF, Gulbrandsen was General Counsel of Lunar Corporation and Bone Care International. Both companies developed and commercialized technologies arising from research at UW-Madison. Gulbrandsen is Vice Chair and board member of the Morgridge Institute for Research. He also serves on the Board of WiCell Research Institute. Gulbrandsen is admitted to practice before the United States Patent and Trademark Office and served as a member of the Patent Public Advisory Council for the United States Patent and Trademark Office. Gulbrandsen and his wife, Mary, have three children and four grandchildren.
Thomas studied Biology in Germany, USA and UK. He became R&D Director with biotech start-up Axxima Pharmaceuticals AG (Munich, Ger) working on drug development in infectious diseases. Thomas joined Merck KGaA, Darmstadt, Germany in 2004 and lead large global R&D teams focusing on evaluating new business opportunities in the Life Science arena. In 2017 he accepted the offer to become corporate "Head of Silicon Valley Innovation Hub", Menlo Park, CA, to tap into the local and NA eco system.
Thomas is member of several boards of Merck KGaA incl the Innovation Steering Committee, MBAP (Merck Bioethics Advisory Panel) and chairing the SCROC (Stem Cell Research Oversight Committee). He is professor at the TU Darmstadt University teaching novel technologies in pharma research; he received several awards (e.g. Boehringer Ingelheim Research Award, MERCK Award, EMBL, ICRF and BIF Fellowships) and published more than 70 peer-reviewed papers and 25 patents. Focus of his expertise is signal transduction, novel modalities, cultured meat and biosensors.
Eva is a General Partner at Fika Ventures, an early stage technology fund investing in companies that leverage the power of data as a core component of their business model. Prior to Fika, Eva was a founding GP at Susa Ventures. She is a serial entrepreneur and founder, with a company experience portfolio including Applied Semantics (AdSense), Factual, Google, Youtube and Navigating Cancer. She is active in the non-profit sector, serving on the boards of California Community Foundation and UCLA's Technology Development Group. She was recently the Entrepreneur-in-Residence for the city of Los Angeles working with Mayor Eric Garcetti and his team. Eva holds an MBA from Cornell and a BA from Harvard.
Andrei Iancu was Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO). He was confirmed unanimously (94-0 floor vote) by the Senate in February 2018, and enjoyed strong bipartisan support throughout his tenure. In this role, Mr. Iancu provided leadership and oversight to one of the largest intellectual property offices in the world, with approximately 13,000 employees and an annual budget of over $3.5 billion. He was also the principal advisor in the Administration on domestic and international intellectual property policy matters.
Mr. Iancu has been recognized as one of the country’s top intellectual property lawyers. Prior to his service in government, Mr. Iancu represented clients in a wide variety of industries, appeared regularly in federal courts and at the USPTO, published and spoke often on intellectual property and law firm management issues, and taught patent law at the UCLA School of Law. He was also the firm-wide Managing Partner of Irell & Manella LLP.
Dr. Jakobovits is the Founder, President and CEO of Adicet Bio, Inc., a biopharmaceutical company, which together with its wholly-owned Israeli subsidiary, Adicet Bio Israel, is focused on the development of next-generation immunotherapies. Prior to starting Adicet, Dr. Jakobovits served as a Venture Partner with OrbiMed Advisors. From 2010-2013 she served as President & Founding CEO of Kite Pharma Inc., a leader in autologous T cell therapy. Prior to Kite Pharma, she served as Executive Vice President, Head of Research and Development at Agensys Inc., an affiliate of Astellas Pharma, Inc. Before Agensys’ acquisition in 2007, for a deal value of $537 million, she served as Senior Vice President, Technology and Corporate Development and Chief Scientific Officer, and led Agensys transition from a small gene discovery lab into a fully integrated biotech company with a proprietary portfolio of novel cancer targets and a clinical pipeline of cancer therapeutic antibodies. Before Agensys, Dr. Jakobovits served as Director, Discovery Research and Principal Scientist at Abgenix Inc., which was spun out of Cell Genesys based on XenoMouse® technology developed under her leadership. Abgenix was acquired by Amgen for $2.2 billion.
Dr. Jakobovits received her Ph.D. in Life Sciences from the Weizmann Institute of Sciences, Israel, and was a postdoctoral fellow at Genentech and at UCSF. Dr. Jakobovits is an author of over 50 scientific publications and inventor on over 100 patents.
Rajit Malhotra is a Technology Entrepreneur, Executive and Investor. He invests in, advises and helps build rapidly growing, early stage companies. He has a deep expertise in healthcare, as well as extensive experience across a broad range of industries, including Biopharma, Artificial Intelligence, Energy, and Real Estate. He is the Executive Chairman at AmperSand Biopharma, a rapidly growing company. He is also the Executive Chairman of Tour Engine, a novel combustion engine technology based business. He also advises other companies, both within and outside his investment portfolio.
Rajit founded his first business while still in college, building it into the largest retail chain of Paint Technology stores in Oman & Dubai. He was a co-founder and board member of one of India’s largest biotech companies, Shantha Biotech, which was sold to Sanofi Aventis for over $850M in 2009. Amongst a few other ventures, he engineered a rapid performance turnaround at one of the largest pharmacy chains in Oman.
In 2002, Rajit joined the LA office of McKinsey, and eventually took over as the Managing Partner for the SoCal region, until leaving in 2016. While at McKinsey, he counseled CEOs, Boards and senior executives at Fortune 500 companies He was a leader of the healthcare, public sector and EPNG practices. His healthcare clients include biopharma, medical products manufacturers, providers and distribution companies. He accumulated extensive experience across a broad range of C-suite level issues, including organizational transformation, growth strategy, commercial excellence, capability building, mergers and acquisitions and driving change at scale.
Rajit lives in Los Angeles with his two children and golden retriever. He is actively involved with several civic and charitable projects. Rajit is on the Board of the UCLA Technology Development Corporation and the CAFAM Museum. He has been on the Dean’s Alumni Leadership Council at Harvard University’s Kennedy School, a member of the Southern California Leadership Council, and the Board of the Saban Free Clinic. He was a founding member of the Oman Chapter of YEO in the mid 1990s and is currently a member, and on the Executive Committee, of the Bel Air Chapter of YPO.
Rajit received an MPA/ID from Harvard University’s Kennedy School and his MBA from Kellogg at Northwestern University. He has dual undergraduate degrees in Business and Liberal Arts from the Wharton School and the College at the University of Pennsylvania, where he graduated Summa Cum Laude.
John T. Mapes
John Mapes is the Managing Partner of Aurora Capital Partners and Chairman of the Investment Committee. He has spent his entire 23 year professional career in the financial services sector.
Aurora Capital Partners was founded in 1991. With assets under management in excess of $2.0 billion, Aurora is a private equity investment firm that invests across a number of funds in middle market companies across the country. Aurora Capital Partners is currently investing out of its sixth fund. The Firm acquires controlling interests in companies in such sectors as: specialty manufacturing, distribution and software/tech-enabled services. In addition to leading the Firm’s private equity practice, John is a member of the Firm’s Executive Committee. While he has extensive board experience with other Aurora-invested companies through the years, John currently sits on the Boards of National Technical Systems and Restaurant Technologies, Inc.
Following his graduation from UCLA with a BA degree in Economics/Business in 1990, where John played varsity tennis for the Bruins, he spent two years with Salomon Brothers, Inc. in both New York and Los Angeles, in their Corporate Finance Group. He left Salomon Brothers to join Aurora in 1992 and then rejoined the Firm after attending and graduating from Harvard Business School in 1995.
John and his wife have a son entering his sophomore year at UCLA and a daughter attending Campbell Hall High School. He has been involved in the community with the Special Olympics and the St. Matthew’s Vestry, which oversees the Church and Episcopal Day School at St. Matthew’s Church. He is also active on behalf of Harvard Business School in California.
His wife Carrie earned a BA in History in 1990 and a Master’s in Education and Multiple Subject Instruction Credential in 1991. Carrie belongs to Women & Philanthropy and is a lifetime member of the Alumni Association. The Mapes endowed five student-athlete scholarships at UCLA—two in men’s tennis, football, men’s basketball, and women’s beach volleyball. Additionally, the Mapes funded a gift to support the construction of new beach volleyball courts at UCLA which will be known on campus as Mapes Beach. John currently serves on the Athletics Centennial Campaign Committee, Chairs the UCLA Athletic Hall of Fame Committee and serves on the UCLA Technology Development Corporation Board.
Jennifer L. Mnookin, Ralph and Shirley Shapiro Professor of Law, became dean of UCLA School of Law in August 2015. A member of the UCLA Law faculty since 2005, she served as Vice Dean for Faculty and Research from 2007 to 2009, and Vice Dean for Faculty Recruitment and Intellectual Life in 2012-13.
As dean, she has worked to build upon UCLA Law’s reputation for excellence and access, and to support a collaborative and engaged environment among the school’s students, renowned faculty and 18,000 alumni. Initiatives she has spearheaded include new student scholarship programs, including the full-tuition Achievement Fellowship Program for high-achieving students who have overcome significant obstacles; new programs in human rights, criminal justice, immigration, and law and technology; UCLA Law’s first alumnae leadership conference; and a significant expansion of clinical opportunities in areas ranging from veterans’ needs to documentary filmmaking. She has also focused energy on the California Bar Exam and the need for cut-score reform.
A leading evidence scholar, Dean Mnookin is founder and faculty co-director of PULSE @ UCLA Law (the Program on Understanding Law, Science & Evidence), and she has published extensively on issues relating to forensic science, expert evidence, evidence theory, the Confrontation Clause, and visual and photographic evidence. In 2020, she was elected to the American Academy of Arts and Sciences. She recently joined the board of trustees of the Law School Admission Council and also serves on the advisory board of the Electronic Privacy Information Center. Dean Mnookin served on the steering committee of the Association of American Law Schools’ Deans Forum from 2016 to 2019, was elected to the American Law Institute in 2011, and spent six years on the National Academy of Science’s Committee on Science, Technology and Law.
Prior to joining UCLA Law, Dean Mnookin was professor of law and Barron F. Black Research Professor at the University of Virginia School of Law, and visiting professor of law at Harvard Law School. She received her A.B. from Harvard University, her J.D. from Yale Law School, and a Ph.D. in History and Social Study of Science and Technology from M.I.T.
Alfred E. Osborne, Jr., is interim dean of the UCLA Anderson School of Management, overseeing its key objectives to conduct essential research, educate students and serve the community. Previously, he served as the school's senior associate dean, overseeing such key initiatives as resource development, alumni relations, corporate initiatives and executive education. A professor of global economics, management and entrepreneurship, Osborne is also the founder and faculty director of Anderson's Harold and Pauline Price Center for Entrepreneurship & Innovation. His academic expertise and interests include social entrepreneurship and the development of a leadership approach that applies business models and methodologies to the nonprofit world. He holds four degrees from Stanford University, including a Ph.D. in business economics and an MBA in finance.
Robert Pacifici, Ph.D.
Robert Pacifici is the Chief Scientific Officer of CHDI Foundation, a private, not-for-profit research organization that works with an international network of scientists to accelerate therapeutics development for Huntington’s disease. Previously he was the Site Director and Chief Scientific Officer at the Research Triangle Park Laboratories of Eli Lilly and Company. There he oversaw the company's global screening and quantitative-biology efforts. Prior to joining Lilly, Pacifici was Vice President of Discovery Technologies at Xencor, a pri¬vately held biotechnology company that applied rational design principles to the development of protein therapeutics. At Amgen for nearly ten years, Pacifici held positions of increasing responsibilities including leadership for their automation, high throughput screening, and information technologies groups.
Pacifici received a BS in Biochemistry from the University of Massachusetts, Amherst, and a PhD in Biochemistry from the University of Southern California. Outside of CHDI, Pacifici currently participates in several external boards and advisory com¬mittees including:
- USC Board of Supervisors of the International Center for Regulatory Science
- Member, Spinal Muscular Atrophy Foundation Scientific Advisory Board
- Member, Akashi Scientific Advisory Board
Pacifici has previously served on:
- Council member for National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) from 2011 till 2014
- Chair, Working Group for the NINDS Anticonvulsant Screening Program
- Chair, NIH/NINDS Spinal Muscular Atrophy Project's Scientific Steering Committee
- Advisor, Marigold Foundation for Myotonic Dystrophy
- Advisor, Cooperative International Neuromuscular Group (CINRG) the clinical research arm of the Duchenne Muscular Dystrophy Research Center (DMDRC) and the Center for Genetic Medicine Research at the Children’s National Medical Center (CNMC)
- Member, Science Advisory Board for Edison Pharmaceuticals
- Member, TREAT ALS Steering Committee
- Member, Pathogenesis of Facioscapulohumeral Muscular Dystrophy advisory board
- Panel of Experts for National Center for Advancing Translational Sciences (NCATS) at NIH, in the NIH Center for Translational Therapeutics (NCTT). This division is home to two programs that seek to advance promising therapeutic agents through late-stage preclinical development: Therapeutics for Rare and Neglected Diseases (TRND), and Bridging Interventional Development Gaps (BrIDGs)
Robert also serves in the non-scientific capacity of President with the Asia America Symphony Association. Robert, his wife Eunjoo, and his two children Sarina and Noah, live in Palos Verdes Estates California. Robert is an avid amateur road-cyclist and a classic BMW enthusiast.
Mr. Pendo joined Oaktree in 2015 from the investment banking boutique of Sandler O'Neill Partners, where he was a managing director focused on the financial services industry. Prior thereto, Mr. Pendo was the chief investment officer of the Troubled Asset Relief Program (TARP) of the U.S. Department of the Treasury, where he was honored with the Distinguished Service Award. There, he built and managed a team of 20 professionals overseeing the Treasury's $200 billion TARP investment activities across multiple industries including AIG, GM and the banks, and all levels of the capital structure. Mr. Pendo began his career at Merrill Lynch, where he spent 18 years, starting in their investment banking division before becoming managing director of the technology industry group. Subsequently, Mr. Pendo was a managing director at Barclays Capital, first serving as co-head of U.S. Investment Banking and then co-head of Global Industrials group. He received a bachelor's degree in economics from Princeton University, cum laude and is a board member of SuperValu Inc.
Jessica joined Experien Group in 2017 to expand the firm’s business development activities and to direct strategic growth initiatives. As Chief Operating Officer, she works closely with the founders on the organization’s thoughtful expansion and management responsibilities such as planning, hiring, business operations and performs due diligence for scalability that ensures the continued delivery of high-value services to all clients. She interfaces with U.S. and international executives, investors, legal representation, and clinical and policy advisors to expand industry networks and to deliver meaningful support to the firm’s clientele and partners. Jessica oversees Experien Group’s operations, leads the business development team and coordinates with senior team members around client communications, deliverables definition, resource planning, budget estimates, project accounting, and results tracking to ensure client satisfaction. She delivers industry presentations representing Experien Group and informs the firm’s collaterals and training materials. Prior to joining Experien Group, Jessica spent six years in leadership roles within Medtronic, where she led sales and market development activities within the Early Technologies division. While at Medtronic, she spearheaded successful, high-impact projects in the areas of strategic sales planning, physician education, collaboration with patient advocacy groups and corporate project management. Previous to that experience, Jessica drove commercial sales activities within the medical device, software, and communications field. She concentrated on driving adoption of paradigm shifting technologies and she remains passionate about patient-centric medical device advancement. Jessica is a health care leader with experience in both medical devices and diagnostics. Jessica earned her BA in Communications and Business Administration from the University of California at Berkeley.
Barbara K. Sosnowski
Barbara Sosnowski is Vice President and Global Head, External R&D Innovation Pharmatherapeutics and WRD External Partnerships. As part of the Pharmatherapeutics team, Barbara is the cluster lead for Cardiovascular Metabolic and Inflammation and Immunology Research Units for externally focused efforts. Dr. Sosnowski has more than 30 years in the health care industry. Prior to joining Pfizer 6 years ago, Barbara was Vice President, Biologics Development of Cardium Therapeutics and was appointed Chief Operating Officer of Tissue Repair Company following Cardium’s acquisition of Tissue Repair Company in August 2006. Prior to the acquisition, Dr. Sosnowski served as President and CEO of Tissue Repair Company. From June 2001 to December 2004 she served as Vice President Research and Development of Selective Genetics Inc. a tissue repair company that developed wound repair, orthopedic and cardiovascular products. At Selective Genetics, she co-invented and helped develop the targeted gene therapy program, both viral and non-viral. Prior to Selective Genetics she was employed by Prizm Pharmaceuticals from October 1992. Prior to joining Prizm, Dr. Sosnowski was at Ligand Pharmaceuticals, where her efforts were focused on identification of small molecule inhibitors of osteoporosis. Dr. Sosnowski received her BA in Biological Sciences from the University of California, Berkeley and PhD in Biological Sciences from Johns Hopkins University. She is also a registered patent agent.